The National Cancer Center (NCC) said it has discovered a biomarker that can distinguish pancreatic cancer patients from healthy individuals "with 100 percent accuracy" and has licensed out the biomarker to New Cancer Cure Bio.

The biomarkers X-100 and X-99 have shown the capability to accurately differentiate between the presence and absence of pancreatic cancer using single-marker tests.

The team, led by Professor Han Sung-sik of the Department of Pancreato-Biliary Surgery, is working to further validate these biomarkers and investigate their feasibility for companion diagnostics.

The team expects the exploration to lead to more efficient clinical trial processes and provide a cost-effective alternative to traditional diagnostic methods such as CT and MRI scans, ultimately reducing healthcare costs and patient burden.

“Once commercialized, this breakthrough in pancreatic cancer diagnostics will make it easier and more accurate to diagnose patients with pancreatic cancer, providing real benefits to patients,” Professor Han said.